Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 8/20 | 0.49 |
| ▸ | PPARA | Q07869 | 7/20 | 0.49 |
| ▸ | ESR1 | P03372 | 5/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 5/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | PPARD | Q03181 | 1/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5994930 | 0.87 | ESR1 (0.52) | PPARGPPARAESR1ESR2PTGS2 | |
| SCHEMBL977514 | 0.85 | PPARA (0.54) | PPARGPPARAESR1ESR2PTGS2 | |
| SCHEMBL977513 | 0.85 | PPARA (0.54) | PPARGPPARAESR1ESR2PTGS2 | |
| SCHEMBL6419166 | 0.85 | PPARA (0.54) | PPARGPPARAESR1ESR2PTGS2 | |
| SCHEMBL5272161 | 0.82 | PPARA (0.48) | PPARGPPARAESR1ESR2PPARD | |
| SCHEMBL4258664 | 0.81 | PPARA (0.52) | PPARGPPARAPPARD | |
| SCHEMBL5379702 | 0.81 | ESR1 (0.45) | PPARGPPARAESR1ESR2PTGS2 | |
| SCHEMBL5379694 | 0.81 | ESR1 (0.45) | PPARGPPARAESR1ESR2PTGS2 | |
| SCHEMBL3991226 | 0.80 | ESR1 (0.45) | PPARAESR1ESR2PTGS2BACE1 | |
| SCHEMBL5384008 | 0.80 | ESR1 (0.45) | PPARAESR1ESR2PTGS2BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090124656-A1 | Heterocyclic Oxime Compounds a Process for Their Preparation and Pharmaceutical Compositions Containing Them | LES LABORATOIRES SERVIER (FR) | 2009-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124656-A1 | Heterocyclic Oxime Compounds a Process for Their Preparation and Pharmaceutical Compositions Containing Them | GPR119, HBB, CYP3A7 | PPARG 969/4885PPARA 1020/4885ESR1 3058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.